Akston Biosciences Receives $2.5M Milestone Payment
Akston Biosciences announced that it has received a $2.5 million milestone payment from Dechra Pharmaceuticals PLC after the successful completion of Dechra’s Proof of Concept study for AKS-321d, a once-a-week canine insulin therapy. The study was conducted at several private veterinary clinics in the United States. Dr. Todd Zion, Akston’s co-founder, President and CEO said, “Successful completion of the PoC sets in motion the full commercial development of this important new therapy.”